Therapeutic efficacy of CXCR3 blockade in an experimental model of severe sepsis

Critical Care

Volumn 16, Issue 5, 2012, Pages

  Herzig, Daniela S ^a   Guo, Yin ^a,b   Fang, Geping ^a   Toliver Kinsky, Tracy E ^a,b   Sherwood, Edward R ^c  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR3 ANTIBODY; CILASTATIN PLUS IMIPENEM; CXCL3 CHEMOKINE; IMMUNOGLOBULIN G; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; CXCR3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COUNT; BODY TEMPERATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; HYPOTHERMIA; INFLAMMATION; MOUSE; NONHUMAN; PERITONEUM LAVAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS; SEPTIC SHOCK; SURVIVAL; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; METABOLISM;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; RECEPTORS, CXCR3; SEPSIS; TREATMENT OUTCOME;

EID: 84866304118     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11642     Document Type: Article

References (33)

1. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011, 89:207-215. 10.1038/icb.2010.158, 21221121.
2. Dagan-Berger M, Feniger-Barish R, Avniel S, Wald H, Galun E, Grabovsky V, Alon R, Nagler A, Ben-Baruch A, Peled A. Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11. Blood 2006, 107:3821-3831. 10.1182/blood-2004-01-0214, 16368892.
3. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, Sahagan BG, Neote K. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998, 187:2009-2021. 10.1084/jem.187.12.2009, 2212354, 9625760.
4. Tominaga M, Iwashita Y, Ohta M, Shibata K, Ishio T, Ohmori N, Goto T, Sato S, Kitano S. Antitumor effects of the MIG and IP-10 genes transferred with poly[d,l-2,4-diaminobutyric acid] on murine neuroblastoma. Cancer Gene Ther 2007, 14:696-705. 10.1038/sj.cgt.7701059, 17514193.
5. Laragione T, Brenner M, Sherry B, Gulko PS. CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis. Arthritis Rheum 2011, 63:3274-3283. 10.1002/art.30573, 3205193, 21811993.
6. Al-Saleh J, el-Eissawy S. The role of T helper cell subsets in pathogenesis of systemic lupus erythematosus and their relation to disease activity. Egypt J Immunol 2006, 13:41-48.
7. Gu D, Chen Z, Zhao H, Du W, Xue F, Ge J, Sui T, Wu H, Liu B, Lu S, Zhang L, Yang R. Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia. Hum Immunol 2010, 71:586-591. 10.1016/j.humimm.2010.02.010, 20153790.
8. Roep BO, Kleijwegt FS, van Halteren AG, Bonato V, Boggi U, Vendrame F, Marchetti P, Dotta F. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin Exp Immunol 2010, 159:338-343. 10.1111/j.1365-2249.2009.04087.x, 2819499, 20059481.
9. Li B, Xu W, Xu L, Jiang Z, Wen Z, Li K, Xiong S. I-TAC is a dominant chemokine in controlling skin intragraft inflammation via recruiting CXCR3+ cells into the graft. Cell Immunol 2010, 260:83-91. 10.1016/j.cellimm.2009.09.004, 19875106.
10. Fulton AM. The chemokine receptors CXCR4 and CXCR3 in cancer. Curr Oncol Rep 2009, 11:125-131. 10.1007/s11912-009-0019-1, 19216844.
11. Stiles LN, Hosking MP, Edwards RA, Strieter RM, Lane TE. Differential roles for CXCR3 in CD4+ and CD8+ T cell trafficking following viral infection of the CNS. Eur J Immunol 2006, 36:613-622. 10.1002/eji.200535509, 16479546.
12. Thair SA, Walley KR, Nakada TA, McConechy MK, Boyd JH, Wellman H, Russell JA. A single nucleotide polymorphism in NF-κB inducing kinase is associated with mortality in septic shock. J Immunol 2011, 186:2321-2328. 10.4049/jimmunol.1002864, 21257964.
13. Punyadeera C, Schneider EM, Schaffer D, Hsu HY, Joos TO, Kriebel F, Weiss M, Verhaegh WF. A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. J Emerg Trauma Shock 2010, 3:26-35. 10.4103/0974-2700.58666, 2823139, 20165718.
14. Chen HL, Hung CH, Tseng HI, Yang RC. Plasma IP-10 as a predictor of serious bacterial infection in infants less than 4 months of age. J Trop Pediatr 2011, 57:145-151. 10.1093/tropej/fmr021, 21447596.
15. Ng PC, Li K, Chui KM, Leung TF, Wong RP, Chu WC, Wong E, Fok TF. IP-10 is an early diagnostic marker for identification of late-onset bacterial infection in preterm infants. Pediatr Res 2007, 61:93-98. 10.1203/01.pdr.0000250207.95723.96, 17211148.
16. Herzig DS, Driver BR, Fang G, Toliver-Kinsky TE, Shute EN, Sherwood ER. Regulation of lymphocyte trafficking by CXC chemokine receptor 3 during septic shock. Am J Respir Crit Care Med 2012, 185:291-300. 10.1164/rccm.201108-1560OC, 22135342.
17. Etogo AO, Nunez J, Lin CY, Toliver-Kinsky TE, Sherwood ER. NK but not CD1-restricted NKT cells facilitate systemic inflammation during polymicrobial intra-abdominal sepsis. J Immunol 2008, 180:6334-6345. 3413484, 18424757.
18. Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 2009, 1173:310-317. 10.1111/j.1749-6632.2009.04813.x, 19758167.
19. Kivisakk P, Trebst C, Liu Z, Tucky BH, Sorensen TL, Rudick RA, Mack M, Ransohoff RM. T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin Exp Immunol 2002, 129:510-518. 10.1046/j.1365-2249.2002.01947.x, 1906480, 12197893.
20. Singh UP, Venkataraman C, Singh R, Lillard JW. CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocr Metab Immune Disord Drug Targets 2007, 7:111-123. 10.2174/187153007780832109, 17584151.
21. Baker MS, Chen X, Rotramel AR, Nelson JJ, Lu B, Gerard C, Kanwar Y, Kaufman DB. Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10 modulates posttransplantation graft-site lymphocytic infiltrates and prolongs functional graft survival in pancreatic islet allograft recipients. Surgery 2003, 134:126-133. 10.1067/msy.2003.213, 12947308.
22. Wijtmans M, Verzijl D, Leurs R, de Esch IJ, Smit MJ. Towards small-molecule CXCR3 ligands with clinical potential. ChemMedChem 2008, 3:861-872. 10.1002/cmdc.200700365, 18442035.
23. Chen X, Mihalic J, Deignan J, Gustin DJ, Duquette J, Du X, Chan J, Fu Z, Johnson M, Li AR, Henne K, Sullivan T, Lemon B, Ma J, Miao S, Tonn G, Collins T, Medina JC. Discovery of potent and specific CXCR3 antagonists. Bioorg Med Chem Lett 2012, 22:357-362. 10.1016/j.bmcl.2011.10.120, 22130135.
24. Liu J, Fu Z, Li AR, Johnson M, Zhu L, Marcus A, Danao J, Sullivan T, Tonn G, Collins T, Medina J. Optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg Med Chem Lett 2009, 19:5114-5118. 10.1016/j.bmcl.2009.07.032, 19632842.
25. Wijtmans M, Verzijl D, Bergmans S, Lai M, Bosch L, Smit MJ, de Esch IJ, Leurs R. CXCR3 antagonists: quaternary ammonium salts equipped with biphenyl- and polycycloaliphatic-anchors. Bioorg Med Chem 2011, 19:3384-3393. 10.1016/j.bmc.2011.04.035, 21570852.
26. Agostini C, Calabrese F, Rea F, Facco M, Tosoni A, Loy M, Binotto G, Valente M, Trentin L, Semenzato G. Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 2001, 158:1703-1711. 10.1016/S0002-9440(10)64126-0, 1891930, 11337368.
27. Hildebrandt GC, Corrion LA, Olkiewicz KM, Lu B, Lowler K, Duffner UA, Moore BB, Kuziel WA, Liu C, Cooke KR. Blockade of CXCR3 receptor:ligand interactions reduces leukocyte recruitment to the lung and the severity of experimental idiopathic pneumonia syndrome. J Immunol 2004, 173:2050-2059.
28. Fierro MT, Comessatti A, Quaglino P, Ortoncelli M, Osella Abate S, Ponti R, Novelli M, Bernengo MG. Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sezary syndrome. Dermatology 2006, 213:284-292. 10.1159/000096191, 17135733.
29. Kerr AR, Kirkham LA, Kadioglu A, Andrew PW, Garside P, Thompson H, Mitchell TJ. Identification of a detrimental role for NK cells in pneumococcal pneumonia and sepsis in immunocompromised hosts. Microbes Infect 2005, 7:845-852. 10.1016/j.micinf.2005.02.011, 15893495.
30. Badgwell B, Parihar R, Magro C, Dierksheide J, Russo T, Carson WE. Natural killer cells contribute to the lethality of a murine model of Escherichia coli infection. Surgery 2002, 132:205-212. 10.1067/msy.2002.125311, 12219013.
31. Barkhausen T, Frerker C, Putz C, Pape HC, Krettek C, van Griensven M. Depletion of NK cells in a murine polytrauma model is associated with improved outcome and a modulation of the inflammatory response. Shock 2008, 30:401-410. 10.1097/SHK.0b013e31816e2cda, 18391857.
32. Marquardt N, Wilk E, Pokoyski C, Schmidt RE, Jacobs R. Murine CXCR3+CD27bright NK cells resemble the human CD56bright NK-cell population. Eur J Immunol 2010, 40:1428-1439. 10.1002/eji.200940056, 20186880.
33. Harding M, Kubes P. Innate immunity in the vasculature: interactions with pathogenic bacteria. Curr Opin Microbiol 2012, 15:85-91. 10.1016/j.mib.2011.11.010, 22189442.